Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Invested Capital (2016 - 2021)

Historic Invested Capital for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $1.3 billion.

  • Neurocrine Biosciences' Invested Capital rose 949.32% to $1.3 billion in Q3 2021 from the same period last year, while for Sep 2021 it was $1.3 billion, marking a year-over-year increase of 949.32%. This contributed to the annual value of $1.1 billion for FY2020, which is 244.28% down from last year.
  • According to the latest figures from Q3 2021, Neurocrine Biosciences' Invested Capital is $1.3 billion, which was up 949.32% from $1.3 billion recorded in Q2 2021.
  • In the past 5 years, Neurocrine Biosciences' Invested Capital registered a high of $1.3 billion during Q3 2021, and its lowest value of $247.9 million during Q1 2017.
  • For the 5-year period, Neurocrine Biosciences' Invested Capital averaged around $1.0 billion, with its median value being $1.0 billion (2019).
  • In the last 5 years, Neurocrine Biosciences' Invested Capital crashed by 4011.43% in 2017 and then skyrocketed by 25574.32% in 2018.
  • Quarter analysis of 5 years shows Neurocrine Biosciences' Invested Capital stood at $889.6 million in 2017, then grew by 12.21% to $998.3 million in 2018, then increased by 15.64% to $1.2 billion in 2019, then decreased by 2.44% to $1.1 billion in 2020, then rose by 19.52% to $1.3 billion in 2021.
  • Its last three reported values are $1.3 billion in Q3 2021, $1.3 billion for Q2 2021, and $1.2 billion during Q1 2021.